Gland Pharma’s Manufacturing Scale-Up Key For Vaccine Opportunity: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We met the management of Gland Pharma Ltd. to get insights on key business aspects and the recently announced vaccine opportunity. Here are the key takeaways -
The company recently announced an agreement with the Russian Direct Investment Fund to supply 252 million doses (five doses/vials) of the Sputnik V vaccine.
The company would implement the technology transfer of the drug substance to its manufacturing facilities and set up commercial bioreactors in parallel. Thereafter, the company would manufacture the drug substance and undertake the filling of the drug product into vials under aseptic conditions.
The commercial production is expected to commence from Q3 FY22 and be executed over a 12-13 months period.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.